Vigilant Biosciences will launch an oral rinse test for oral cancer at the American Society of Clinical Oncology (ASCO) 2016 annual meeting in Chicago.
The test, called OraMark, allows earlier detection of oral cancer by measuring the biomarker CD44 combined with total protein, the company said. It will be available in the second half of 2016 through OncAlert Labs.
An abstract showing an association between oral cavity and oropharyngeal cancers and salivary CD 44 and total protein levels will be among the studies published online during the meeting, which will be held June 3-7.
